市場調查報告書

原發性硬化性膽管炎:至2030年的市場分析,流行病學,市場預測

Primary Sclerosing Cholangitis - Market Insights, Epidemiology, and Market Forecast-2030

出版商 DelveInsight Business Research LLP 商品編碼 955859
出版日期 內容資訊 英文 125 Pages
商品交期: 最快1-2個工作天內
價格
原發性硬化性膽管炎:至2030年的市場分析,流行病學,市場預測 Primary Sclerosing Cholangitis - Market Insights, Epidemiology, and Market Forecast-2030
出版日期: 2020年07月01日內容資訊: 英文 125 Pages
簡介

原發性硬化性膽管炎(PSC),是特徵為發炎,纖維化,肝內和肝外膽管的破壞等的免疫介導性慢性肝疾病,引起膽汁停滯,膽管狹窄,肝纖維化,肝硬化,門脈高壓,肝功能代償不全等的可能性。

原發性硬化性膽管炎(PSC)的治療包括減少瘙癢和黃疸的藥物,治療感染的抗生素和維生素補充劑,因為PSC患者通常缺乏維生素A,D和K。在某些情況下,手術可打開常見的主要堵塞物膽管也是必要的。另外,可能需要進行肝移植,並且在某些情況下可以治愈PSC。

本報告提供美國,德國,法國,義大利,西班牙,英國,由於關於日本的到主要7個國家的至2030年的PSC的流行病學展望調查,提供與疾病概要,流行病學患者數,各國流行病學,治療和管理,未支援的需求,新的治療方法,市場展望等資訊。

目錄

第1章 主要調查結果

第2章 摘要整理

第3章 SWOT分析

第4章 市場概要

  • 2017年的市場佔有率
  • 2030年的市場佔有率

第5章 疾病的背景和概要

  • 簡介
  • 病因
  • 徵兆與症狀
  • 危險因素與遺傳學
  • 臨床表現型
  • 病理生理學
    • PSC的免疫病理學
  • 關聯的疾病和併發症
  • 臨床表現
  • 診斷調查

第6章 流行病學和患者數

  • 主要調查結果
  • 主要7個國家的患者數
  • 前提和根據:主要7個國家

第7章 各國流行病學

  • 美國
    • 患者數
    • 盛行率
    • PSC併發症
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第8章 治療和管理

  • 指南
  • 病人歷程
  • 案例研究
    • 美國的案例

第9章 未支援的需求

第10章 新治療方法

  • Cilofexor:Gilead Sciences
  • HTD1801:HighTide Biopharma Pty Ltd
  • NMG282:NGM Biopharmaceuticals
  • Ocaliva:Intercept Pharmaceuticals
  • Norursodeoxycholic酸:Dr Falk Pharma

第11章 其他有潛力的藥劑候補

  • Volixibat:Mirum Pharma
  • A4250:Albireo AB

第12章 開發中止的治療藥

  • Seladelpar:CymaBay Therapeutics
  • DUR-928:Durect
  • BTT1023:Accorda
  • Maralixibat:Mirum Pharma

第13章 開發中斷的治療藥

  • Cenicriviroc:AbbVie

第14章 主要7個國家的市場分析

  • 主要調查結果
  • 主要7個國家的市場規模

第15章 各國市場展望

  • 前提和根據
  • 美國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 英國
  • 日本

第16章 市場成長要素

第17章 市場障礙

第18章 附錄

  • 調查手法

章19:DelveInsight的服務內容

第21章 免責聲明

第22章:關於DelveInsight

目錄
Product Code: DIMI0931

DelveInsight's 'Primary Sclerosing Cholangitis -Market Insights, Epidemiology, and Market Forecast-2030' report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology as well as the market trends of Primary Sclerosing Cholangitis in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The Primary Sclerosing Cholangitis market report provides analysis regarding current treatment practices, emerging drugs like BIO101, Bimagrumab, potential therapies, market share of the individual therapies, and historical, current and forecasted Primary Sclerosing Cholangitis market size from 2017 to 2030, segmented by seven major markets.

The report also covers current Primary Sclerosing Cholangitis treatment practice/algorithm, guidelines, market drivers, market barriers and unmet medical needs to curate best of the opportunities. It assesses the underlying potential of the market.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Primary Sclerosing Cholangitis - Disease Understanding and Treatment Algorithm

Overview:

Primary Sclerosing Cholangitis (PSC) is an immune-mediated chronic liver disease characterized by inflammation, fibrosis and destruction of intrahepatic and/or extra-hepatic bile ducts leading to cholestasis, bile duct strictures and hepatic fibrosis, which in turn, may progress to cirrhosis, portal hypertension, and hepatic decompensation.

Patients might present with cholestasis (elevation in alkaline phosphatase and γ-glutamyl transferase) after either screening in at-risk patients (typically with inflammatory bowel disease) or general health screening. Alternatively, particularly in patients with inflammatory bowel disease, Primary Sclerosing Cholangitis can be identified through the presence of compatible cholangiographic features even in patients with normal serum biochemistry. However, false-positive magnetic resonance cholangiopancreatography (MRCP) findings in this asymptomatic and biochemically normal population might also occur, leaving uncertainty as to the value of MRCP screening in asymptomatic patients with inflammatory bowel disease.

Treatment

Treatment for Primary Sclerosing Cholangitis (PSC) includes medication to reduce itching and jaundice, antibiotics to treat infections and vitamin supplements since people with PSC are often deficient in vitamins A, D and K. In some cases, surgery to open major blockages in the common bile duct also is necessary. In addition, liver transplantation may be required, and in some cases, can cure PSC. The main focus of treatment therapies is retardation plus reversal of the disease process and management of progressive disease and related complications.

This chapter covers the details of conventional and current medical therapies available for the treatment of Primary Sclerosing Cholangitis. It also provides Primary Sclerosing Cholangitis treatment guidelines across the United States and Europe.

DelveInsight's Primary Sclerosing Cholangitis market report gives a thorough understanding of the disease by including details such as disease definition, symptoms, types, grading, pathophysiology, and diagnosis. It also provides Primary Sclerosing Cholangitis treatment algorithms and treatment guidelines in the US, Europe, and Japan.

Epidemiology:

The Primary Sclerosing Cholangitis epidemiology chapters provide insights about historical and current Primary Sclerosing Cholangitis patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Primary Sclerosing Cholangitis epidemiology is segmented by the prevalent cases of Primary Sclerosing Cholangitis, the prevalence of Primary Sclerosing Cholangitis by gender, comorbidities associated with Primary Sclerosing Cholangitis. Besides, the report includes a thorough analysis of all segments.

According to DelveInsight's , the total prevalent population of Primary Sclerosing Cholangitis in seven major markets was 55,340 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

Among all the seven major markets, total prevalent cases for Primary Sclerosing Cholangitis were highest in the United States, followed by Germany. Spain accounted for the least number of prevalent cases among the 7MM.

Drug Chapters:

This segment encloses the detailed analysis of the drugs in the Primary Sclerosing Cholangitis pipeline. It also helps understand the Primary Sclerosing Cholangitis clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.

Currently, there are no effective medical treatment options for the management of PSC. Off-label ursodeoxycholic acid (UDCA), antibiotics, antihistamines and immunosuppressants are administered for symptomatic management of PSC. Trials of novel therapeutic agents are limited by the time taken to reach clinically significant endpoints.

Market Outlook:

The market size of Primary Sclerosing Cholangitis is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounted for the largest Primary Sclerosing Cholangitis market size. Among EU5 countries, Germany, in 2017, had the largest market size with USD 25.46 million, while Spain had the smallest market size of USD 0.34 million.

Drugs Uptake:

This section focuses on the rate of uptake of the potential drugs in the Primary Sclerosing Cholangitis market or expected to get launched in the market during the study period 2017-2030. The analysis covers Primary Sclerosing Cholangitis market uptake by drugs; patient uptake by therapies; and sale of each drug.

It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

GS-9674 (Gilead Sciences), norUrsodeoxycholic Acid (Dr Falk Pharma GmbH), HTD1801 (HighTide Biopharma Pty Ltd), Obeticholic Acid (Intercept Pharmaceuticals), and NGM282 (NGM Biopharmaceuticals, Inc.) are the major players that will alter the market dynamics in the coming years, during the forecasted period 2020-2030.

Primary Sclerosing Cholangitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics.

Pipeline Development Activities:

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning Primary Sclerosing Cholangitis.

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working in Primary Sclerosing Cholangitis domain through primary research to fill the data gaps and validate our secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We have performed the competitive and market Intelligence analysis of the Primary Sclerosing Cholangitis Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. Besides, the inclusion of the analysis entirely depends upon the data availability.

Report Highlights::

  • In the coming years, Primary Sclerosing Cholangitis market scenario is expected to experience a positive shift across the 7MM due to a robust pipeline.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II and Phase III), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Primary Sclerosing Cholangitis Report Insights:

  • Patient Population
  • Therapeutic Approaches
  • Primary Sclerosing Cholangitis Pipeline Analysis
  • Primary Sclerosing Cholangitis Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Primary Sclerosing Cholangitis Report Key Strengths:

  • 11-years Forecast
  • 7MM Coverage
  • Primary Sclerosing Cholangitis Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Primary Sclerosing Cholangitis Report Assessment:

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What was the Primary Sclerosing Cholangitis market share (%) distribution in 2017 and how it would look like in 2030?
  • What would be the Primary Sclerosing Cholangitis total market size as well as market size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM and which country will have the largest Primary Sclerosing Cholangitis market size during the forecast period (2017-2030)?
  • At what CAGR, the Primary Sclerosing Cholangitis market is expected to grow in 7MM during the forecast period (2017-2030)?
  • What would be the Primary Sclerosing Cholangitis market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the Primary Sclerosing Cholangitis market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden and unmet needs of Primary Sclerosing Cholangitis?
  • What is the historical Primary Sclerosing Cholangitis patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of Primary Sclerosing Cholangitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Primary Sclerosing Cholangitis?
  • Out of all 7MM countries, which country would have the highest prevalent population of Primary Sclerosing Cholangitis during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

  • What are the current options for the Primary Sclerosing Cholangitis treatment, along with the approved therapy?
  • What are the current treatment guidelines for the treatment of Primary Sclerosing Cholangitis in the USA, Europe, and Japan?
  • How many companies are developing therapies for the treatment of Primary Sclerosing Cholangitis?
  • How many therapies are developed by each company for Primary Sclerosing Cholangitis ?
  • How many are emerging therapies in mid-stage, and late stage of development for Primary Sclerosing Cholangitis treatment?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Primary Sclerosing Cholangitis therapies?
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Primary Sclerosing Cholangitis and their status?
  • What are the key designations that have been granted for the emerging therapies for Primary Sclerosing Cholangitis?
  • What is the global historical and forecasted market of Primary Sclerosing Cholangitis?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the Primary Sclerosing Cholangitis market
  • To understand the future market competition in the Primary Sclerosing Cholangitis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Primary Sclerosing Cholangitis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Primary Sclerosing Cholangitis market
  • To understand the future market competition in the Primary Sclerosing Cholangitis market

Which geography accounted for the largest Primary Sclerosing Cholangitis market size?

The United States accounted for the largest Primary Sclerosing Cholangitis market size.

What is forecasted Primary Sclerosing Cholangitis size in 2030?

DelveInsight estimates an increase in Primary Sclerosing Cholangitis Market Size during the study period, 2017-2030

What are the present Primary Sclerosing Cholangitis market drivers?

Market opportunity, Increase in research activities, Genome-wide association studies for PSC

What are the Primary Sclerosing Cholangitis market barriers?

Lack of country-specific epidemiology data, Problems associated with disease management, Unavailability of biomarkers, Shortcomings of trials

How many companies are developing drugs for Primary Sclerosing Cholangitis?

Currently, five key pharma players are developing the drug for Primary Sclerosing Cholangitis

Which are the leading companies in Primary Sclerosing Cholangitis market?

Key Players - Gilead Sciences, HighTide Biopharma Pty Ltd, NGM Biopharmaceuticals, Intercept Pharmaceuticals, Dr Falk Pharma Gmbh

How is epidemiology segmented for Primary Sclerosing Cholangitis?

Prevalent cases of Primary Sclerosing Cholangitis, Prevalence of Primary Sclerosing Cholangitis by gender, Comorbidities associated with Primary Sclerosing Cholangitis

Table of Contents

1 Key Insights

2 Executive Summary of Primary Sclerosing Cholangitis

3 SWOT Analysis for Primary Sclerosing Cholangitis

4 Primary Sclerosing Cholangitis Market Overview at a Glance

  • 4.1 Market Share (%) Distribution of PSC in 2017
  • 4.2 Market Share (%) Distribution of PSC in 2030

5 Disease Background and Overview

  • 5.1 Introduction
  • 5.2 Etiology
  • 5.3 Signs and Symptoms
  • 5.4 Risk Factors and genetics
  • 5.5 Clinical Phenotypes
  • 5.6 Pathophysiology
    • 5.6.1 Immunopathology of PSC
  • 5.7 Associated Diseases and Complications
  • 5.8 Clinical Presentation
  • 5.9 Diagnostic Investigations

Cancer surveillance in PSC

6 Epidemiology and Patient Population

  • 6.1 Key Findings
  • 6.2 Total Prevalent Population of Primary Sclerosing Cholangitis in 7MM
  • 6.3 Assumption and Rationale: 7MM

7 Country Wise-Epidemiology of Primary Sclerosing Cholangitis

  • 7.1 The United States
    • 7.1.1 Prevalent cases of Primary Sclerosing Cholangitis in the United States
    • 7.1.2 Prevalence of Primary Sclerosing Cholangitis by Gender in the United States
    • 7.1.3 Comorbidities associated with Primary Sclerosing Cholangitis in the United States
  • 7.2 Germany
    • 7.2.1 Prevalent cases of Primary Sclerosing Cholangitis in Germany
    • 7.2.2 Prevalence of Primary Sclerosing Cholangitis by Gender in Germany
    • 7.2.3 Comorbidities associated with Primary Sclerosing Cholangitis in Germany
  • 7.3 France
    • 7.3.1 Prevalent cases of Primary Sclerosing Cholangitis in France
    • 7.3.2 Prevalence of Primary Sclerosing Cholangitis by Gender in France
    • 7.3.3 Comorbidities associated with Primary Sclerosing Cholangitis in France
  • 7.4 Italy
    • 7.4.1 Prevalent cases of Primary Sclerosing Cholangitis in Italy
    • 7.4.2 Prevalence of Primary Sclerosing Cholangitis by Gender in Italy
    • 7.4.3 Comorbidities associated with Primary Sclerosing Cholangitis in Italy
  • 7.5 Spain
    • 7.5.1 Prevalent cases of Primary Sclerosing Cholangitis in Spain
    • 7.5.2 Prevalence of Primary Sclerosing Cholangitis by Gender in Spain
    • 7.5.3 Comorbidities associated with Primary Sclerosing Cholangitis in Spain
  • 7.6 The United Kingdom
    • 7.6.1 Prevalent cases of Primary Sclerosing Cholangitis in the UK
    • 7.6.2 Prevalence of Primary Sclerosing Cholangitis by Gender in the UK
    • 7.6.3 Comorbidities associated with Primary Sclerosing Cholangitis in the UK
  • 7.7 Japan
    • 7.7.1 Prevalent cases of Primary Sclerosing Cholangitis in Japan
    • 7.7.2 Prevalence of Primary Sclerosing Cholangitis by Gender in Japan
    • 7.7.3 Comorbidities associated with Primary Sclerosing Cholangitis in Japan

8 Treatment and Management

  • 8.1 Guidelines
    • 8.1.1 American College of Gastroenterology Guidelines
    • 8.1.2 AASLD Guidelines for treatment and management of PSC
    • 8.1.3 British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis
  • 8.2 Patient Journey
  • 8.3 Case study
    • 8.3.1 Primary Sclerosing Cholangitis: As case Discussion in the US

9 Unmet Needs

10 Emerging Therapies

  • 10.1 Cilofexor: Gilead Sciences
    • 10.1.1 Product Description
    • 10.1.2 Other Development Activities
    • 10.1.3 Clinical Development
      • 10.1.3.1 Clinical Trials Information
    • 10.1.4 Safety and Efficacy
  • 10.2 HTD1801: HighTide Biopharma Pty Ltd
    • 10.2.1 Product Description
    • 10.2.2 Other Development Activities
    • 10.2.3 Clinical Development
      • 10.2.3.1 Clinical Trials Information
  • 10.3 NMG282: NGM Biopharmaceuticals
    • 10.3.1 Product Description
    • 10.3.2 Other Development Activities
    • 10.3.3 Clinical Development
      • 10.3.3.1 Clinical Trials Information
    • 10.3.4 Safety and Efficacy
  • 10.4 Ocaliva: Intercept Pharmaceuticals
    • 10.4.1 Product Description
    • 10.4.2 Other Development Activities
    • 10.4.3 Clinical Development
      • 10.4.3.1 Clinical Trials Information
    • 10.4.4 Safety and Efficacy
  • 10.5 Norursodeoxycholic acid: Dr Falk Pharma
    • 10.5.1 Product Description
    • 10.5.2 Other Development Activities
    • 10.5.3 Clinical Development
      • 10.5.3.1 Clinical Trials Information
    • 10.5.4 Safety and Efficacy

11 Other Promising Candidates

  • 11.1 Volixibat: Mirum Pharma
    • 11.1.1 Product description
  • 11.2 A4250: Albireo AB
    • 11.2.1 Product description

12 Discontinued Therapies

  • 12.1 Seladelpar: CymaBay Therapeutics
    • 12.1.1 Product Description
  • 12.2 DUR-928: Durect
    • 12.2.1 Product Description
  • 12.3 BTT1023: Accorda
    • 12.3.1 Product Description
  • 12.4 Maralixibat: Mirum Pharma

13 Dormant Therapies

  • 13.1 Cenicriviroc: AbbVie
    • 13.1.1 Product Description

14 Primary Sclerosing Cholangitis (PSC): Seven Major Market Analysis

  • 14.1 Key Findings
  • 14.2 Market Size of Primary Sclerosing Cholangitis (PSC) in 7MM

15 Market Outlook by Country

  • 15.1 Assumption and Rationale
  • 15.2 United States
    • 15.2.1 Total Market size of Primary sclerosing cholangitis (PSC)
    • 15.2.2 Primary Sclerosing Cholangitis (PSC) Market Size by Therapies
  • 15.3 EU5 Countries
    • 15.3.1 Germany
      • 15.3.1.1 Total Market size of Primary sclerosing cholangitis (PSC)
      • 15.3.1.2 Primary Sclerosing Cholangitis (PSC) Market Size by Therapies
    • 15.3.2 France
      • 15.3.2.1 Total Market size of Primary sclerosing cholangitis (PSC)
      • 15.3.2.2 Primary Sclerosing Cholangitis (PSC) Market Size by Therapies
    • 15.3.3 Italy
      • 15.3.3.1 Total Market size of Primary sclerosing cholangitis (PSC)
      • 15.3.3.2 Primary Sclerosing Cholangitis (PSC) Market Size by Therapies
    • 15.3.4 Spain
      • 15.3.4.1 Total Market size of Primary sclerosing cholangitis (PSC)
      • 15.3.4.2 Primary Sclerosing Cholangitis (PSC) Market Size by Therapies
    • 15.3.5 United Kingdom
      • 15.3.5.1 Total Market size of Primary sclerosing cholangitis (PSC)
      • 15.3.5.2 Primary Sclerosing Cholangitis (PSC) Market Size by Therapies
    • 15.3.6 Japan
      • 15.3.6.1 Total Market size of Primary sclerosing cholangitis (PSC)
      • 15.3.6.2 Primary Sclerosing Cholangitis (PSC) Market Size by Therapies

16 Market Drivers

17 Market Barriers

18 Appendix

  • 18.1 Report Methodology

19 DelveInsight Capabilities

21 Disclaimer

22 About DelveInsight

List of Tables

  • Table 1: Summary of Primary sclerosing cholangitis Market, Epidemiology, and Key Events (2017-2030)
  • Table 2: Phenotypic variants of primary sclerosing cholangitis: Terms and features
  • Table 3: Total cases of Primary Sclerosing Cholangitis in 7MM (2017-2030)
  • Table 4: Prevalent cases of Primary Sclerosing Cholangitis in the United States (2017-2030)
  • Table 5: Prevalence of Primary Sclerosing Cholangitis by Gender in the United States (2017-2030)
  • Table 6: Comorbidities associated with PSC in the United States (2017-2030)
  • Table 7: Prevalent cases of Primary Sclerosing Cholangitis in Germany (2017-2030)
  • Table 8: Prevalence of Primary Sclerosing Cholangitis by Gender in Germany (2017-2030)
  • Table 9: Comorbidities associated with PSC in Germany (2017-2030)
  • Table 10: Prevalent cases of Primary Sclerosing Cholangitis in France (2017-2030)
  • Table 11: Prevalence of Primary Sclerosing Cholangitis by Gender in France (2017-2030)
  • Table 12: Comorbidities associated with PSC in France (2017-2030)
  • Table 13: Prevalent cases of Primary Sclerosing Cholangitis in Italy (2017-2030)
  • Table 14: Prevalence of Primary Sclerosing Cholangitis by Gender in Italy (2017-2030)
  • Table 15: Comorbidities associated with PSC in Italy (2017-2030)
  • Table 16: Prevalent cases of Primary Sclerosing Cholangitis in Spain (2017-2030)
  • Table 17: Prevalence of Primary Sclerosing Cholangitis by Gender in Spain (2017-2030)
  • Table 18: Comorbidities associated with PSC in Spain (2017-2030)
  • Table 19: Prevalent cases of Primary Sclerosing Cholangitis in the UK (2017-2030)
  • Table 20: Prevalence of Primary Sclerosing Cholangitis by Gender in the UK (2017-2030)
  • Table 21: Comorbidities associated with PSC in the UK (2017-2030)
  • Table 22: Prevalent cases of Primary Sclerosing Cholangitis in Japan (2017-2030)
  • Table 23: Prevalence of Primary Sclerosing Cholangitis by Gender in Japan (2017-2030)
  • Table 24: Comorbidities associated with PSC in Japan (2017-2030)
  • Table 25: Cilofexor, Clinical Trial Description, 2020
  • Table 26: HTD1801, Clinical Trial Description, 2020
  • Table 27: NGM282, Clinical Trial Description, 2020
  • Table 28: Ocaliva, Clinical Trial Description, 2020
  • Table 29: norUDCA, Clinical Trial Description, 2020
  • Table 30: 7 Major Market Size of PSC in USD Million (2017-2030)
  • Table 31: The US Market size of PSC in USD Million (2017-2030)
  • Table 32: The US market size of PSC by Therapies in USD Million (2017-2030)
  • Table 33: Germany Market size of PSC in USD Million (2017-2030)
  • Table 34: Germany market size of PSC by Therapies in USD Million (2017-2030)
  • Table 35: France Market size of PSC in USD Million (2017-2030)
  • Table 36: France market size of PSC by Therapies in USD Million (2017-2030)
  • Table 37: Italy Market size of PSC in USD Million (2017-2030)
  • Table 38: Italy market size of PSC by Therapies in USD Million (2017-2030)
  • Table 39: Spain Market size of PSC in USD Million (2017-2030)
  • Table 40: Spain market size of PSC by Therapies in USD Million (2017-2030)
  • Table 41: UK Market size of PSC in USD Million (2017-2030)
  • Table 42: UK market size of PSC by Therapies in USD Million (2017-2030)
  • Table 43: Japan Market size of PSC in USD Million (2017-2030)
  • Table 44:Japan market size of PSC by Therapies in USD Million (2017-2030)

List of Figures

  • Figure 1: SWOT Analysis
  • Figure 2: Pathophysiology of Primary sclerosing cholangitis
  • Figure 3: Cholangiocarcinoma surveillance in patients with primary sclerosing cholangitis
  • Figure 4: Cholangiocarcinoma surveillance in patients with primary sclerosing cholangitis
  • Figure 5: Total prevalent cases of Primary Sclerosing Cholangitis in 7MM (2017-2030)
  • Figure 6: Prevalent cases of Primary Sclerosing Cholangitis in the United States (2017-2030)
  • Figure 7: Prevalence of Primary Sclerosing Cholangitis by Gender in the United States(2017-2030)
  • Figure 8: Comorbidities associated with PSC in the United States (2017-2030)
  • Figure 9: Prevalent cases of Primary Sclerosing Cholangitis in Germany (2017-2030)
  • Figure 10: Prevalence of Primary Sclerosing Cholangitis by Gender in Germany (2017-2030)
  • Figure 11: Comorbidities associated with PSC in Germany (2017-2030)
  • Figure 12: Prevalent cases of Primary Sclerosing Cholangitis in France (2017-2030)
  • Figure 13: Prevalence of Primary Sclerosing Cholangitis by Gender in France (2017-2030)
  • Figure 14: Comorbidities associated with PSC in France (2017-2030)
  • Figure 15: Prevalent cases of Primary Sclerosing Cholangitis in Italy (2017-2030)
  • Figure 16: Prevalence of Primary Sclerosing Cholangitis by Gender in Italy (2017-2030)
  • Figure 17: Comorbidities associated with PSC in Italy (2017-2030)
  • Figure 18: Prevalent cases of Primary Sclerosing Cholangitis in Spain (2017-2030)
  • Figure 19: Prevalence of Primary Sclerosing Cholangitis by Gender in Spain (2017-2030)
  • Figure 20: Comorbidities associated with PSC in Spain (2017-2030)
  • Figure 21: Prevalent cases of Primary Sclerosing Cholangitis in the UK (2017-2030)
  • Figure 22: Prevalence of Primary Sclerosing Cholangitis by Gender in the UK (2017-2030)
  • Figure 23: Comorbidities associated with PSC in the UK (2017-2030)
  • Figure 24: Prevalent cases of Primary Sclerosing Cholangitis in Japan (2017-2030)
  • Figure 25: Prevalence of Primary Sclerosing Cholangitis by Gender in Japan (2017-2030)
  • Figure 26: Comorbidities associated with PSC in Japan (2017-2030)
  • Figure 27: Patient Journey for PSC
  • Figure 28: Unmet needs of PSC
  • Figure 29: 7 Major Market Size of PSC in USD Million (2017-2030)
  • Figure 30: Market Size of PSC in the United States, USD Millions (2017-2030)
  • Figure 31: The U.S. market size of PSC by therapies in USD Million (2017-2030)
  • Figure 32: Market Size of PSC in Germany, USD Millions (2017-2030)
  • Figure 33: Germany market size of PSC by therapies in USD Million (2017-2030)
  • Figure 34: Market Size of PSC in France, USD Millions (2017-2030)
  • Figure 35: France market size of PSC by therapies in USD Million (2017-2030)
  • Figure 36: Market Size of PSC in Italy, USD Millions (2017-2030)
  • Figure 37: Italy market size of PSC by therapies in USD Million (2017-2030)
  • Figure 38: Market Size of PSC in Spain, USD Millions (2017-2030)
  • Figure 39: Spain market size of PSC by therapies in USD Million (2017-2030)
  • Figure 40: Market Size of PSC in UK, USD Millions (2017-2030)
  • Figure 41: UK market size of PSC by therapies in USD Million (2017-2030)
  • Figure 42: Market Size of PSC in Japan, USD Millions (2017-2030)
  • Figure 43: Japan market size of PSC by therapies in USD Million (2017-2030)
  • Figure 44: Market Drivers for PSC
  • Figure 45: Market Barriers for PSC